KALA BIO
KALA BIO is a clinical-stage biopharmaceutical company developing innovative stem-cell-derived therapies for rare and severe eye diseases.
Company facts
- Founded
- 2009
- Employees
- 10
- Headquarters
- United States
- Type
- Startup
About
KALA BIO is a clinical-stage biopharmaceutical company developing innovative stem-cell-derived therapies for rare and severe eye diseases. Its flagship candidate, KPI-012, is a human mesenchymal stem cell secretome (MSC-S) that delivers growth factors, protease inhibitors, and neurotrophic factors to promote corneal healing and is currently in U.S. FDA-designated orphan and Fast-Track trials for persistent corneal epithelial defect. The company also explores MSC-S for limbal stem cell deficiency and retinal degenerative conditions such as retinitis pigmentosa and Stargardt disease. By harnessing the regenerative potential of MSC-S, KALA BIO seeks to address unmet needs in vision-threatening disorders with a unique biologics platform.